[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ridgeback Biotherapeutics, LP\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":16,"phases":4,"briefSummary":17,"conditions":18,"keywords":20,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":32,"locationsCount":4},"100444418",false,"NCT05067166","Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP","Open-Label, Expanded Access Protocol of a Human Monoclonal Antibody, Ansuvimab (mAb114), Administered As a Therapeutic to Ebola-Infected Patients or As a High-Risk Ebola Post-Exposure Prophylaxis","Inclusion Criteria:\n\n* Male or female with laboratory confirmed (based on local standard of care) EBOV infection or with recent high-risk EBOV exposure as determined by a treating Physician or designee.\n* Able to provide proof of identity to the satisfaction of the clinical team\n* Able and willing to complete the informed consent process personally, or if the patient is unable to do so, then informed consent completed by a legally-authorized representative according to local laws and regulations.\n\nExclusion Criteria:\n\n\\- Any medical condition that, in the opinion of the Treating Physician, would place the patient at an unreasonably increased risk through participation in this treatment protocol.","ALL","EXPANDED_ACCESS","The human monoclonal antibody (mAb), ansuvimab (mAb114), will be provided to Ebola-infected patients as either a treatment or as PEP under an expanded access protocol. Ansuvimab is administered at 50 mg\u002Fkg as a single intravenous (IV) infusion",[19],"Ebola Virus Disease",[21,22,23,24,25,26],"EBANGA","orthoebolavirus zairense, EBOV","ansuvimab","Zaire ebolavirus, EVD","Compassionate Use","Ebola","AVAILABLE","2024-12-12",{"date":30,"type":31},"2024-12-17","ACTUAL",{"name":33,"class":34},"Ridgeback Biotherapeutics, LP","INDUSTRY",""]